SUMMARY Twenty four neonates at high risk of anaerobic sepsis were treated with intravenous metronidazole, 7 5 mg/kg, 8 hourly, for a mean period of 5 days. The highest observed concentration after the first dose (mean ± SD) 9-6 ± 4 0 mg/l (56-1 ± 23-4 ,mol/l) was significantly lower (P<0.001) than the highest observed concentration after the final dose (mean + SD) 19-3 ± 8-6 mg/I (112 7 + 50-2 ,umol/1). The overall metronidazole half life was (mean ± SD) 23 4 ± 13-1 hours. The half life after the first dose (mean ± SD) 21-9 ± 10 1 hours was not appreciably different from the half life after the final dose (mean ± SD) 21 -6 ± 12 4 hours. The concentrations of the major metabolite of metronidazole (20396RP) also rose appreciably during treatment. No side effects of metronidazole were noted and its extended half life in neonates suggests that less frequent dosage would be appropriate.
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Anaerobic bacteria are more common than aerobes in the genital tract of healthy women.1 There is a risk of fetal infection by ascending anaerobic organisms2 where there* is prolonged rupture of fetal membranes before delivery, particularly with maternal pyrexia, and offensive or purulent discharge. Anaerobic infection is also a potential hazard to The whole blood samples were stored at -20°C until assayed. The concentrations of both metronidazole and its major human oxidative metabolite 20396RP (1-(2 hydroxyethyl) -2 hydroxymethyl-5 nitroimidazole), which also possesses some antianaerobic activity, were measured using a specific high pressure liquid chromatographic method.7
A 1 compartment open model has been used to represent the pharmacokinetics of metronidazole.8 When 3 points were available to calculate the elimination constant the method of least squares was used to find the linear regression.
Results
Two infants in group 1 died aged 1 day and 4 daysrespectively, from respiratory distress complicated by air leaks and intraventricular haemorrhage. Their birthweights were 780 g and 790 g. One infant in group 2 died aged 21 days from Enterobacter septicaemia and peritonitis. Her birthweight was 790 g. No infants showed any side effects that might have been caused by metronidazole and no case of anaerobic sepsis was identified by culture during this study.
The highest mean concentration (peak) of metronidazole measured from 1-5 hours after the first dose was 9-6 mg/l (range 4-3-24.1 mg/l) (56.1 ,umol/l (25. 1-140-7 ,tmol/l)) and 10-15 hours after the final dose was 19.31 mg/l (range 8.8-28 9 mg/l) (112-7 .tmol/l/l (51.4-168.8 ,umol/l)). The peak median concentration of 20396RP after the first dose of metronidazole was 0 7 mg/l (range 0 1-5 mg/1) (3-7 ,umol/l (0-5-26.7 V.mol/l)) and after the final dose was 5.2 mg/l (range 2-2-7 0 mg/l) (27 8 ,umol/l (I 1 * 7-37. 4 ,umol/1)).
A total of 35 measurements of the blood elimination half life of metronidazole were made during this study-5 after the first dose, 7 after the second, 4 Table) . There was no important difference in the half lives following the first, second, or final doses. 
